Stereotaxis

STXS

Medical - Equipment & Services · Healthcare

Price

$1.42

-0.02 (-1.39%)

Market Cap

$139.1M

Exchange

New York Stock Exchange Arca

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Weak

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+20.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 75.6M (2021) → 91.0M (2025)

Winston Score History

The full picture

Stereotaxis makes robotic systems used by doctors to perform heart procedures. Its main product, the Genesis robotic magnetic navigation system, uses magnets to guide thin wires through a patient's heart to treat abnormal heart rhythms, a condition called arrhythmia. The company sells its equipment to hospitals and cardiac catheterization labs, primarily in the United States and Europe.

Stereotaxis earns money by selling its robotic systems to hospitals and then charging ongoing fees for disposable supplies, service contracts, and software used during each procedure. The company is small, with a market cap around $200 million, and its technology is specialized enough that few direct competitors offer the same magnetic navigation approach. However, Stereotaxis is currently losing significant money, with deep operating losses, so its main challenge is expanding the number of hospitals using its systems and growing recurring revenue fast enough to reach profitability before it needs additional funding.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-12.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-6.2% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$9M/ year

→ Flat (-4% vs prior year)

29.0% of revenue

1.6x the sector average (18%)

Steady R&D investment year-over-year

Insider Activity

29.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~8 months

$10M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Stereotaxis has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

58.5%

Premium pricing power — 58.5% gross margin

Profit after running costs

Operating Margin

-59.6%

Losing money on operations — -59.6%

Return on the money invested

ROCE

-125.6%

Weak — -125.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-5.5%

Shrinking sales (-5.5% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-51.6%

Burning cash (-51.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial